Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease.

Abstract:

:We investigated the use of 'prophylactic' donor lymphocyte infusions (DLI) containing 1 x 107 CD3+ cells, given at 30, 60 and 90 days post-allogeneic blood and marrow transplantation (BMT), following conditioning with fludarabine 30 mg/m(2)/4 days and melphalan 70 mg/m(2)/2 days. GVHD prophylaxis consisted of cyclosporin A (CsA) 2 mg/kg daily with early tapering by day 60. Our goals were the rapid achievement of chimerism and disease control, providing an immunological platform for DLIs to treat refractory patients with hematological malignancies. Twelve heavily pre-treated patients with life expectancy less than 6 months were studied; none were in remission. Diagnoses were AML (n = 4), MDS (n = 1), ALL (n = 3), CML (n = 3) and multiple myeloma (n = 1). Response rate was 75%. Three patients are alive at a median of 450 days (range, 450-540). Two patients are in remission of CML in blast crisis and AML for more than 14 months. Median survival is 116 days (range, 25-648). Six patients received 12 DLIs; three patients developed acute GVHD after the first infusion and were excluded from further DLIs, but no GVHD occurred among patients receiving subsequent DLIs. One patient with CML in blast crisis went into CR after the first DLI. The overall incidence of acute GVHD was 70%. Primary causes of death were infections (n = 3), acute GVHD (n = 3), chronic GVHD (n = 1) and disease relapse (n = 2). We observed high response and chimerism rates at the expense of an excessive incidence of GVHD. DLI given at day +30 post BMT caused GVHD in 50% of the patients, and its role in this setting remains unclear.

journal_name

Bone Marrow Transplant

authors

de Lima M,Bonamino M,Vasconcelos Z,Colares M,Diamond H,Zalcberg I,Tavares R,Lerner D,Byington R,Bouzas L,da Matta J,Andrade C,Carvalho L,Pires V,Barone B,Maciel C,Tabak D

doi

10.1038/sj.bmt.1702726

subject

Has Abstract

pub_date

2001-01-01 00:00:00

pages

73-8

issue

1

eissn

0268-3369

issn

1476-5365

journal_volume

27

pub_type

杂志文章
  • Toxicity of high-dose busulphan and cyclophosphamide as conditioning therapy for allogeneic bone marrow transplantation in adults with haematological malignancies.

    abstract::The toxicity of the conditioning regimen high-dose busulfan (BU) 16 mg/kg followed by cyclophosphamide (CY) 200 mg/kg has been analysed in 60 adult patients (mean age 36 +/- 9 years) with haematological malignancies, a third of whom had advanced disease, all received the graft from fully HLA-identical siblings. Signif...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Bandini G,Belardinelli A,Rosti G,Calori E,Motta MR,Rizzi S,Benini C,Tura S

    更新日期:1994-05-01 00:00:00

  • Patient education in allogeneic hematopoietic cell transplant: what patients wish they had known about quality of life.

    abstract::Quality of life (QOL) is increasingly recognized as an important clinical outcome of hematopoietic cell transplantation (HCT), but patient education is often overlooked. The aim of the current qualitative study was to examine education regarding post-HCT QOL from the patient's perspective. Allogeneic HCT recipients pa...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2013.158

    authors: Jim HS,Quinn GP,Gwede CK,Cases MG,Barata A,Cessna J,Christie J,Gonzalez L,Koskan A,Pidala J

    更新日期:2014-02-01 00:00:00

  • Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir.

    abstract::Twenty-five patients with hematologic malignancies (n = 21) or aplastic anemia (n = 4) undergoing an allogeneic BMT from an HLA-identical sibling developed cytomegalovirus (CMV) antigenemia at a mean interval from BMT of 41 days (range 16-141 days). All patients were treated at the time of antigenemia in the absence o...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:

    authors: Bacigalupo A,van Lint MT,Tedone E,Moro F,Sanna MA,Longren M,Trespi G,Frassoni F,Occhini D,Gualandi F

    更新日期:1994-06-01 00:00:00

  • Virus recovery from stools of patients undergoing bone marrow transplantation.

    abstract::Diarrhea in marrow transplant recipients is a frequent complication attributable to non-infectious events such as acute GVHD or infectious events such as viral gastroenteritis. Rotavirus and enteric adenovirus are the most frequent viral pathogens. To determine the frequency of these infections, we prospectively exami...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Troussard X,Bauduer F,Gallet E,Freymuth F,Boutard P,Ballet JJ,Reman O,Leporrier M

    更新日期:1993-12-01 00:00:00

  • Gene therapy for hematopoietic and immune disorders.

    abstract::Gene therapy is a novel approach under investigation for the treatment of genetic diseases, cancer and AIDS. Hematopoietic stem cells would be the target cell for correction of hemoglobinopathies, immune deficiencies and lysosomal storage diseases. Retroviral vectors derived from murine leukemia viruses have been used...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:

    authors: Kohn DB

    更新日期:1996-12-01 00:00:00

  • G-CSF alone vs cyclophosphamide plus G-CSF in PBPC mobilization of patients with lymphoma: results depend on degree of previous pretreatment.

    abstract::We performed a randomized study to compare 'G-CSF alone' (administered at dose of 10 mcg/kg/day) and 'cyclophosphamide plus G-CSF' (cyclophosphamide at dose of 4 g/m(2) and G-CSF at dose of 10 microg/kg/day), as PBPC mobilization schedules in 52 patients with NHL or HD. Randomization was stratified according to the am...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1038/sj.bmt.1703912

    authors: Milone G,Leotta S,Indelicato F,Mercurio S,Moschetti G,Di Raimondo F,Tornello A,Consoli U,Guido G,Giustolisi R

    更新日期:2003-05-01 00:00:00

  • Early iron reduction programme for thalassaemia patients after bone marrow transplantation.

    abstract::Thirty thalassaemia patients received iron reduction starting at around 3 months post transplant. Sixteen received desferrioxamine and nine had phlebotomy, five patients had desferrioxamine followed by phlebotomy. The desferrioxamine group had higher serum ferritin levels at the start of iron reduction as compared to ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1702212

    authors: Li CK,Lai DH,Shing MM,Chik KW,Lee V,Yuen PM

    更新日期:2000-03-01 00:00:00

  • Large scale recovery and characterization of stromal cell-associated primitive haemopoietic progenitor cells from filter-retained human bone marrow.

    abstract::Bone marrow aspirates are composed of two cellular compartments, an abundant buffy coat suspension and a minor particulate fraction. The particulate fraction is routinely removed by filtration prior to transplantation in order to reduce the risk of embolism. This study shows that the filter-retained fraction includes ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701616

    authors: Blazsek I,Delmas Marsalet B,Legras S,Marion S,Machover D,Misset JL

    更新日期:1999-04-01 00:00:00

  • Mucosal melanoma following autologous stem cell transplantation for non-Hodgkin's lymphoma (NHL).

    abstract::The incidence of secondary malignancy following autologous stem cell transplantation (ASCT) is increasing. We describe a patient with stage IVB Hodgkin's disease who developed primary amelanotic malignant melanoma of the tongue 18 months following autologous stem cell transplantation. She was treated by partial glosse...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Ben-Yosef R,Braverman I,Saah D,Nagler R,Shohat S,Or R,Nagler A

    更新日期:1996-11-01 00:00:00

  • Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.

    abstract::Transplantation-associated thrombotic microangiopathy (TA-TMA) is a feared complication of allogeneic hematopoietic SCT (HSCT) owing to its high mortality rate. The use of calcineurin inhibitors or sirolimus (SIR) for GVHD prophylaxis has been suggested as a potential risk factor. However, the impact of tacrolimus (TA...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2014.17

    authors: Labrador J,López-Corral L,López-Godino O,Vázquez L,Cabrero-Calvo M,Pérez-López R,Díez-Campelo M,Sánchez-Guijo F,Pérez-López E,Guerrero C,Alberca I,Del Cañizo MC,Pérez-Simón JA,González-Porras JR,Caballero D

    更新日期:2014-05-01 00:00:00

  • Pentostatin (2'deoxycoformycin) for the treatment of lymphoid neoplasms.

    abstract::Knowledge of the vital role of adenosine deaminase in lymphatic tissues has led to the development of enzyme inhibitors for treatment of lymphoid neoplasms. Deoxycoformycin is a potent ADA inhibitor and has been shown to be active in acute lymphoblastic leukemia at high doses but associated with unpredictable toxicity...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Ho AD,Thaler J,Willemze R,Lauria F,Derossi G,Kuse R,Stryckmans P,Blanc CM,Cataldo F,McVie G

    更新日期:1989-01-01 00:00:00

  • Tacrolimus and mycofenolate mofetil as GvHD prophylaxis following nonmyeloablative conditioning and unrelated hematopoietic SCT for adult patients with advanced hematologic diseases.

    abstract::In the current study, we evaluated a combination of tacrolimus and mycophenolate mofetil (MMF) as GvHD prophylaxis in 50 patients undergoing truly nonmyeloablative (NM; 90 mg/m(2) fludarabine, 2 Gy TBI) hematopoietic SCT (HSCT) from unrelated donors. Median patient age was 51 years (range, 25-67 years). After a median...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2010.167

    authors: Zohren F,Schroeder T,Czibere A,Fenk R,Bruns I,Kondakci M,Saure C,Haas R,Kobbe G

    更新日期:2011-05-01 00:00:00

  • Successful second allogeneic peripheral blood stem cell transplantation and donor lymphocyte infusion in patients with relapsed acute leukemia using the same donors as for the initial allogeneic bone marrow transplantation.

    abstract::We report the successful treatment of two acute lympho- blastic leukemia (ALL) patients who relapsed following allogeneic bone marrow transplantation (allo-BMT) with allogeneic peripheral blood sem cell transplantation(allo-PBSCT) and donor lymphocyte infusion (DLI) from the same HLA-identical related donors as those ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704059

    authors: Ishikawa J,Maeda T,Kashiwagi H,Yoshida H,Takahashi I,Kawamoto SI,Yamada M,Kato H,Nishiura T,Tomiyama Y,Matsuzawa Y

    更新日期:2003-06-01 00:00:00

  • Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease.

    abstract::Corticosteroid-resistant GVHD is difficult to manage and is associated with high morbidity and mortality. Cyclophosphamide (Cy) is an established immunosuppressive and cytotoxic drug widely used as part of pretransplant conditioning regimens. In a retrospective study of 15 patients who had not responded to corticoster...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704829

    authors: Mayer J,Krejcí M,Doubek M,Pospísil Z,Brychtová Y,Tomíska M,Rácil Z

    更新日期:2005-04-01 00:00:00

  • Freezing the graft is not necessary for autotransplants for plasma cell myeloma and lymphomas.

    abstract::We studied rates of granulocyte and platelets recovery in 359 consecutive subjects receiving blood cell infusions in the context of autotransplants for plasma cell myeloma (N = 216) and lymphomas (N = 143). Blood cells were mobilised with filgrastim given for 4-5 days and collected after a median of 2 (range, 1-2) aph...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-017-0047-7

    authors: Kardduss-Urueta A,Gale RP,Gutierrez-Aguirre CH,Herrera-Rojas MA,Murrieta-Álvarez I,Perez-Fontalvo R,Ruiz-Delgado GJ,Ruiz-Rojas G,Jaimovich G,Feldman L,Labastida-Mercado N,Endara A,Castro M,Galindo-Becerra S,Cardona-Molina MA

    更新日期:2018-04-01 00:00:00

  • Towards a global system of vigilance and surveillance in unrelated donors of haematopoietic progenitor cells for transplantation.

    abstract::Safety of living donors is critical to the success of blood, tissue and organ transplantation. Structured and robust vigilance and surveillance systems exist as part of some national entities, but historically no global systems are in place to ensure conformity, harmonisation and the recognition of rare adverse events...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2013.104

    authors: Shaw BE,Chapman J,Fechter M,Foeken L,Greinix H,Hwang W,Phillips-Johnson L,Korhonen M,Lindberg B,Navarro WH,Szer J

    更新日期:2013-11-01 00:00:00

  • Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies.

    abstract::We report results of a thiotepa-based conditioning in haploidentical stem cell transplantation (haplo-SCT) with posttransplant cyclophosphamide (PT-CY) and antithymocyte globulin (ATG), for unmanipulated peripheral blood stem cell (PBSC) transplants, in 80 patients with hematological malignancies. Patients in complete...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-019-0726-7

    authors: Peric Z,Mohty R,Bastos J,Brissot E,Battipaglia G,Belhocine R,Sestili S,Giannotti F,Vekhoff A,Ledraa T,Legrand O,Lapusan S,Isnard F,Labopin M,Bonnin A,Mediavilla C,Rubio MT,Ruggeri A,Duléry R,Malard F,Mohty M

    更新日期:2020-04-01 00:00:00

  • Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation.

    abstract::Reduced-intensity conditioning (RIC) extends hematopoietic stem cell transplants (HSCT) to elderly or debilitated patients who are not candidates for HSCT. The incidence and outcomes of cardiac complications have been reported following myeloablative HSCT. We assessed the incidence and outcomes of cardiac complication...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2009.97

    authors: Peres E,Levine JE,Khaled YA,Ibrahim RB,Braun TM,Krijanovski OI,Mineishi S,Abidi MH

    更新日期:2010-01-01 00:00:00

  • Bone marrow transplantation in Hong Kong.

    abstract::Comprehensive programmes for BMT started in Hong Kong in 1990. As of September 1993, there are a total of 13 BMT beds in Government-funded University Hospitals performing about 110 transplants per year or 18 transplants per million population per year. So far, 194 transplants were performed: allogeneic BMT (72.2%), au...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Chiu EK,Yuen P,Chan TK

    更新日期:1994-06-01 00:00:00

  • First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: the experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working Party.

    abstract::Extragonadal germ cell tumors are classified according to the staging system of the International Germ Cell Cancer Collaborative Group (IGCCCG). The 5-year overall and disease-free survival rates for poor prognosis patients are 41 and 48%, respectively after standard-dose chemotherapy. We report the experience of the ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704704

    authors: Rosti G,De Giorgi U,Wandt H,Lioure B,Leyvraz S,Kolbe K,Papiani G,Ballardini M,Kulekci A,Demirer T,Solid Tumours Working Party.

    更新日期:2004-12-01 00:00:00

  • Evaluation of chimerism after bone marrow transplantation with single locus minisatellite DNA probes.

    abstract::The origin of cells in almost all allogeneic donor-recipient pairs can be determined through the use of highly polymorphic minisatellite DNA probes. Single-locus probes were cloned from hypervariable fragments in a human DNA fingerprint detected with a multi-locus probe. While each probe is highly polymorphic and locu...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Harano H,Maruta A,Matsuzaki M,Kanamori H,Fukawa H,Noguchi T,Miyashita H,Ogawa K,Motomura S,Kodama F

    更新日期:1993-09-01 00:00:00

  • Evaluating the association between histological manifestations of cord colitis syndrome with GVHD.

    abstract::Cord colitis syndrome (CCS) is a recently proposed clinical entity characterized by a persistent diarrheal illness after cord blood transplantation (CBT), which is not caused by GVHD or CMV colitis. CCS is histologically characterized by chronic active colitis with granulomatous inflammation and Paneth cell metaplasia...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2013.44

    authors: Shimoji S,Kato K,Eriguchi Y,Takenaka K,Iwasaki H,Miyamoto T,Oda Y,Akashi K,Teshima T

    更新日期:2013-09-01 00:00:00

  • ABO-incompatible bone marrow transplantation: a GITMO survey of current practice in Italy and comparison with the literature.

    abstract::ABO incompatibility is not considered a contraindication for allogeneic haematopoietic stem cell transplantation (HSCT) despite its association with several immunohaematological complications. At present, there is no general agreement concerning the best methods to reduce these problems. To survey current practice rel...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/sj.bmt.1704579

    authors: Raimondi R,Soli M,Lamparelli T,Bacigalupo A,Arcese W,Belloni M,Rodeghiero F,Gruppo Italiano Trapianto di Midolla Osseo.

    更新日期:2004-08-01 00:00:00

  • Monoclonal rat anti-human lymphocyte antibody Campath-1 binds to T and B lymphocytes but effectively lyses only T cells.

    abstract::Binding and human complement-mediated T and B lymphocyte lysis were investigated in bone marrow samples obtained from 15 normal donors and 12 patients with a variety of malignant disorders undergoing marrow cryopreservation prior to autologous bone marrow transplantation. All marrow samples were obtained during remiss...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Gazitt Y,Or R,Mumcuoglu M,Slavin S

    更新日期:1987-12-01 00:00:00

  • Autologous BMT in high risk patients with CALLA-positive ALL: possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement.

    abstract::Autologous BMT (auto-BMT) has been conducted for 17 high-risk common ALL antigen (CALLA)-positive non-T cell type ALL patients. Ex vivo purging of leukemia cells from infused BM cells was performed using complement and three kinds of mouse monoclonal antibodies reactive to CALLA-positive leukemia cells: NL-1 (IgG2a), ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:

    authors: Morishima Y,Miyamura K,Kojima S,Ueda R,Morishita Y,Sao H,Tanimoto M,Ohno R,Sobue R,Hirano M

    更新日期:1993-04-01 00:00:00

  • Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study.

    abstract::The aim of the present trial was to investigate the feasibility of high-dose therapy followed by autologous peripheral blood stem cell transplantation (PBSCT) as a component of front-line treatment in patients with disseminated intermediate- and high-grade non-Hodgkin's lymphoma (NHL) aged 61-65 years. From October 19...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701272

    authors: Moreau P,Milpied N,Voillat L,Colombat P,Mahé B,Rapp MJ,Moreau A,Dupas B,Bulabois CE,Juge-Morineau N,Harousseau JL

    更新日期:1998-06-01 00:00:00

  • Increased plasma level of vascular endothelial glycoprotein thrombomodulin as an early indicator of endothelial damage in bone marrow transplantation.

    abstract::We investigated the nature of hemostatic alterations occurring after bone marrow transplantation. In 45 patients, we evaluated the coagulation parameters, naturally occurring anticoagulants and thrombomodulin at days +15 and +22 after conditioning therapy. It was observed that endothelial cell damage is a central path...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Testa S,Manna A,Porcellini A,Maffi F,Morstabilini G,Denti N,Macchi S,Rosti G,Porcellini G,Cassi D,Ferrari L

    更新日期:1996-08-01 00:00:00

  • Resolution of psoriasis after allogeneic bone marrow transplantation for chronic myelogenous leukemia: late complications of therapy.

    abstract::Treatment of autoimmune disease with bone marrow transplantation (BMT) is under investigation. A few reports of patients undergoing allogeneic BMT for malignant conditions observed the resolution of psoriasis after BMT, with minimal late morbidity. We describe a patient with chronic myelogenous leukemia (CML) whose ps...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702703

    authors: Adkins DR,Abidi MH,Brown RA,Khoury H,Goodnough LT,Vij R,Westervelt P,DiPersio JF

    更新日期:2000-12-01 00:00:00

  • Matched unrelated or matched sibling donors result in comparable outcomes after non-myeloablative HSCT in patients with AML or MDS.

    abstract::The impact of allelic HLA matching in patients with AML and myelodysplastic syndrome (MDS) who receive allogeneic PBSC after a reduced-intensity conditioning (RIC) regimen is unclear. From January 2000 to December 2010, 108 consecutive patients with AML (n=63) and MDS (n=45) received PBSC after RIC in our center, eith...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2013.50

    authors: Robin M,Porcher R,Adès L,Boissel N,Raffoux E,Xhaard A,Larghero J,Gardin C,Himberlin C,Delmer A,Fenaux P,Dombret H,Socié G,Peffault de Latour R

    更新日期:2013-10-01 00:00:00

  • A prospective study of Epstein-Barr virus load in 85 hematopoietic stem cell transplants.

    abstract::EBV viral load (EBV-VL) in PBMC was prospectively determined by semi-quantitative PCR in 85 stem cell transplants (40 genoidentical, 45 non-genoidentical) in order to characterize the kinetics of EBV-VL and to assess the ability of this measure to predict the development of EBV-induced lymphoproliferative disease (EBV...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703331

    authors: Sirvent-Von Bueltzingsloewen A,Morand P,Buisson M,Souillet G,Chambost H,Bosson JL,Bordigoni P

    更新日期:2002-01-01 00:00:00